APAC Protein Therapeutics Market

APAC Protein Therapeutics Market Size (2024 to 2029)

As per the research report, the size of the Asia Pacific Protein Therapeutics market was worth USD 39.52 billion in 2024. It is expected to grow at a CAGR of 7.3% and value USD 52.39 billion by 2029. It captures 20% of the global market.

Protein therapeutics are most often employed in the treatment of chronic ailments like cancer etc. This market has huge potential in the coming years.

Factors such as rising demand for protein treatments, rising prevalence of chronic diseases, and the development of plasma-derived therapies are majorly driving the growth of the APAC protein therapeutics market. Also, the rising frequency of chronic medical disorders is one of the primary reasons driving the market’s growth. 

On the other hand, the increased awareness among the general public of the benefits of protein treatments, such as the low risk of side effects and great efficacy, positively influences the market growth.

 Pharmaceutical companies utilize protein treatments to develop new drugs, and monoclonal antibodies are widely explored and used to treat numerous viral and bacterial disorders.

However, the unexpected outbreak of coronavirus disease presents potential prospects for the protein therapies market. 

During the projected period, rising incidence of chronic diseases such as cancer, cardiovascular disease, and diabetes are expected to fuel the market growth. The acceptance of treatments with great efficiency and low risk of side effects increases among the end-users.

Furthermore, the Asia pacific protein therapeutics market is being propelled forward by increased awareness of protein therapeutics and the growing adoption of plasma-derived medicines to treat chronic diseases. Furthermore, several governments have taken numerous measures to enhance the healthcare sector by creating ideal conditions to help the protein therapies market grow significantly.

However, The market expansion is being stifled by vague government regulations and a clumsy administrative framework. In addition, the high cost of installing and maintaining devices in laboratories is limiting the growth of the APAC protein therapeutics market.

This research report on the APAC protein therapeutics market has been segmented and sub-segmented into the following categories:

By Product:

• Monoclonal Antibodies

• Insulin

• Fusion Protein

• Erythropoietin

• Interferon

• Human Growth Hormone

• Follicle Stimulating Hormone

By Application:

• Metabolic Disorders

• Immunologic Disorders

• Hematological Disorders

• Cancer

• Hormonal Disorders

• Genetic Disorders

• Others

By Therapeutic Modalities: 

• Protein Diagnostics

• Protein Vaccines

• Protein Therapeutics with Special Targeting Activity

• Protein Therapeutics with Enzymatic Or Regulatory Activity

By Country: 

• India

• China

• Japan

• South Korea

• Australia

• New Zealand

• Thailand

• Malaysia

• Vietnam

• Philippines

• Indonesia

• Singapore

• Rest of APAC

Geographically, as emerging nations become more aware of these revolutionary treatment procedures, the Asia Pacific protein therapeutics market is expected to increase at the fastest rate during the projected period. Due to the rapid increase in chronic diseases, improved consumer knowledge, supporting government policies, modernization of health infrastructure, and population growth in developing nations like China and India in this region. In this region, the rising protein treatments use in emerging economies such as China, India, and Japan, expanding the market for protein therapeutics. 

China recorded the largest share of the APAC protein therapeutics market, and it is projected to account for a predominant share during the forecast period. Developing market enterprises, snowballing research and development in the protein therapies sector, the government’s increasing emphasis on immunization to combat various diseases, and a large target population significantly contribute to market growth. 

Furthermore, one of the emerging countries in the Asia Pacific is India. The Indian protein therapeutics market growth is projected to record a promising share in the coming year. Increasing investments and initiatives by the government through medical tourism, improving the healthcare sector, and increasing the prevalence of chronic diseases are driving the market growth. 

Notable participants dominating the Asia Pacific Protein Therapeutics Market profiled in this report are Baxter International Inc., Eli Lilly, and Company, Abbott Laboratories, Amgen Inc., F. Hoffmann-La Roche Ltd. Other players in the market are Novo Nordisk A/S, Pfizer Inc., Johnson & Johnson, Merck & Co., Inc., and Sanofi.